Ovarian Cancer

In this week’s episode, we spoke with the most decorated Olympic gymnast and ovarian cancer survivor Shannon Miller before CURE’s second annual Ovarian Cancer Heroes gala.

Lenvima (lenvatinib) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, according to results from a phase I study.

Treatment with the combination of Keytruda (pembrolizumab), Avastin (bevacizumab) and metronomic cyclophosphamide appeared safe and effective in women with recurrent epithelial ovarian cancer, according to results from an open-label phase 2 study.

Prior exposure to PARP inhibitor treatment may not lead to resistance in future use with these agents in women with recurrent epithelial ovarian cancer, meaning repeat use could become more common.

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose.

Patients with recurrent ovarian cancer who received Zejula (niraparib) maintenance therapy experienced longer progression-free survival, as well as more time without symptoms or toxicity compared with placebo, according to results from the phase 3 ENGOT-OV16/NOVA trial.

The importance of teamwork between patients and their caregivers was a common theme at the second annual Ovarian Cancer Heroes event held in Honolulu, Hawaii.

In this week’s episode, we spoke with actor Scott Foley, who opened up about his experience as a caregiver to his mother after her ovarian cancer diagnosis and why he joined the Not on My Watch movement to help educate others.

From shark genomes to celebs and important updates, here is a quick overview of what is making headlines in the cancer space.

“Love, Gilda” fea­tures never-before-seen diaries, audio and videotapes from the collection of Gilda Radner, who died at age 42 of ovarian cancer.

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

Researchers are evaluating the use of folate receptors to treat platinum-resistant ovarian cancer.

Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.

There is a flood of information available about genetic tests for cancer risk in the media, and even at community events, such as health fairs and senior centers. If these promotions have caught your attention and you are considering testing, there is important information that you should know first.

The addition of the investigational drug alisertib to a paclitaxel regimen showed promising activity in patients with recurrent ovarian cancer or advanced breast cancer.

A recent survey demonstrated the common tradeoffs most patients report regarding treatment decisions, highlighting the importance of shared decision making.

Rather than revisiting the ghosts of cancer treatments past, I’m focused on using what I’ve learned in three years of active treatment and maintenance for incurable, metastatic cancer.

This is the first approval of a PARP inhibitor as a first-line maintenance treatment for BRCA-mutant gynecologic cancers.

The Food and Drug Administration (FDA) approved BRACAnalysis CDx to be used to identify patients with advanced ovarian cancer who have germline BRCA mutations and are eligible for first line treatment with Lynparza (olaparib) after responding to platinum-based chemotherapy.

A new program offers counseling, patient education and vetted referrals to patients and their families.

Maintenance treatment with Lynparza (olaparib) after chemotherapy has been found to significantly extend progression-free survival in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation, according to a recent phase 3 study.

A cancer diagnosis can lead to discussions about family health history, as well as a whole new world to learn about.

Patients with ovarian cancer are living longer than ever.

To receive payment for counseling and increase access to services, a new bill has been introduced so that genetic counselors receive payment for counseling Medicare beneficiaries.

Certain cancer treatments can affect the mouth, so dental health should be a lifelong commitment.

The FDA has granted a priority review designation to a supplemental new drug application (sNDA) for Lynparza (olaparib) tablets for use as a maintenance therapy in patients with newly-diagnosed, BRCA-positive advanced ovarian cancer who achieved a complete or partial response to standard frontline platinum-based chemotherapy.

Families with certain genetic mutations face many complex and personal choices, including how and when to share such information with their children. Mom's Genes is here to help.

Here are some tips on coping with the disease that seems to affect us all.

Here are the top 5 CURE stories for October 2018.

The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.